anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: In Alzheimer's disease (AD), early diagnosis facilitates treatment options and leads to beneficial outcomes for patients, their carers and the healthcare system. The neuropsychological battery of the Uniform Data Set (UDSNB3.0) assesses cognition in ageing and dementia, by measuring scores across different cognitive domains such as attention, memory, processing speed, executive function and language. However, its neuroanatomical correlates have not been investigated using 7 Tesla MRI (7T MRI).
METHODS: We used 7T MRI to investigate the correlations between hippocampal subfield volumes and the UDSNB3.0 in 24 individuals with Amyloidβ-status AD and 18 age-matched controls, with respective age ranges of 60 (42-76) and 62 (52-79) years. AD participants with a Medial Temporal Atrophy scale of higher than 2 on 3T MRI were excluded from the study.
RESULTS: A significant difference in the entire hippocampal volume was observed in the AD group compared to healthy controls (HC), primarily influenced by CA1, the largest hippocampal subfield. Notably, no significant difference in whole brain volume between the groups implied that hippocampal volume loss was not merely reflective of overall brain atrophy. UDSNB3.0 cognitive scores showed significant differences between AD and HC, particularly in Memory, Language, and Visuospatial domains. The volume of the Dentate Gyrus (DG) showed a significant association with the Memory and Executive domain scores in AD patients as assessed by the UDSNB3.0.. The data also suggested a non-significant trend for CA1 volume associated with UDSNB3.0 Memory, Executive, and Language domain scores in AD. In a reassessment focusing on hippocampal subfields and MoCA memory subdomains in AD, associations were observed between the DG and Cued, Uncued, and Recognition Memory subscores, whereas CA1 and Tail showed associations only with Cued memory.
DISCUSSION: This study reveals differences in the hippocampal volumes measured using 7T MRI, between individuals with early symptomatic AD compared with healthy controls. This highlights the potential of 7T MRI as a valuable tool for early AD diagnosis and the real-time monitoring of AD progression and treatment efficacy.
CLINICALTRIALS: GOV: ID NCT04992975 (Clinicaltrial.gov 2023).
Participants will receive 3.0 micrograms/kilogram (μg/kg) PEGPH20 as an intravenous (IV) infusion, twice weekly for Weeks 1 to 3 of Cycle 1 (each cycle consisting of 4 weeks \[Week 4 of every cycle will be a rest week with no treatment\]), then once weekly for Weeks 1 to 3 of Cycle 2 and beyond in combination with 125 milligrams/square meter (mg/m\^2) nab-paclitaxel as an IV infusion and 1000 mg/m\^2 gemcitabine as an IV infusion, once weekly for Weeks 1 to 3 of all treatment cycles. Treatment will continue until disease progression, unacceptable toxicity, death, or withdrawal of consent.
The inflammatory foreign body response (FBR) is the main driver of biomaterial implant failure. Current strategies to mitigate the onset of a FBR include modification of the implant surface, release of anti-inflammatory drugs, and cell-scale implant porosity. The microporous annealed particle (MAP) scaffold platform is an injectable, porous biomaterial composed of individual microgels, which are annealed in situ to provide a structurally stable scaffold with cell-scale microporosity. MAP scaffold does not induce a discernible foreign body response in vivo and, therefore, can be used a "blank canvas" for biomaterial-mediated immunomodulation. Damage associated molecular patterns (DAMPs), such as IL-33, are potent regulators of type 2 immunity that play an important role in tissue repair. In this manuscript, IL-33 is conjugated to the microgel building-blocks of MAP scaffold to generate a bioactive material (IL33-MAP) capable of stimulating macrophages in vitro via a ST-2 receptor dependent pathway and modulating immune cell recruitment to the implant site in vivo, which indicates an upregulation of a type 2-like immune response and downregulation of a type 1-like immune response.
In an embodiment, systems and methods for retrieving medical records are provided. A request for medical records is received from a payor by a records system. The request may include a list of the medical providers and criteria. The criteria may specify whether the payor only wants electronic records or both electronic and non-electronic records. The records system compares the list of providers with a list of providers who use electronic records and determines which providers of the request use electronic records and which providers of the request do not use electronic records. For each medical provider of the request that uses electronic records, the records system may request the records from each provider using an electronic records workflow. For each medical provider of the request that does not use electronic records, the records system may request the records from each provider using a non-electronic request workflow.
Patients will perform the inhalation of the 7% hypertonic saline (following the gold standard recomendation) during 15 minutes. Right after, patients will perform independently their usual session of autogenic drainage during 30 minutes.
The invention relates to a fresh ginger tablet which is a Chinese patent medicine prepared by the following steps: cleaning, disinfecting, peeling and slicing fresh gingers; washing and disinfecting by pure water; spraying brown sugar and traditional Chinese medicines (honeysuckles, rabdosia rubescens and borneol); firstly crushing and mixing; and hermetically packing. The fresh ginger tablet can prevent cold and treat sphagitis and allergic rhinitis. In the morning, the fresh ginger tablet is held in mouth and chewed for 20-30 minutes, so that phlegm which cannot be coughed from the throat is softened and automatically spit out, a current of air in noses crushes, people feel better and no long sneezes and the fresh ginger tablet takes effect immediately. The fresh ginger tablet is used for a relatively long time to cure and has the functions of supplementing calcium and blood. The fresh ginger tablet which is continuously used over one year has a curative effect on gall-stones, kidney stones and hepatitis B virus, which is verified by a hospital. The simple fresh ginger tablet has various curative effects and moreover, the medicaments price every day is not more than two yuan, which is seldom among medicaments.
Treatment group, receives Narrative Exposure Therapy immediately after first assessment. Patients are assessed 1 and 6 months after treatment.
An immunogenic compositions comprising influenza virus antigen derived from at least 5 influenza virus strains and one or more compounds of formula (I) or a physiologically acceptable salt or ester thereof; Wherein R1 represents H or C1-6 alkyl; R2 and R3 independently represent C1-6 alkyl. The composition preferably comprises influenza virus antigens derived from 8-18 influenza virus strains, in particular 15 strains; and preferably from at least two different virus types, in particular types A and B. The compositions preferably comprises at least one influenza virus antigen derived from a H1N1 subtype of type A and at least one derived from a H3N2 subtype of type A. The compound of formula (I) is preferably either dimethylglycine or trimethylglycine or both. The composition is preferably prepared via freezing, heat-treating and/or freeze drying a single aqueous composition comprising the influenza virus antigens and the compound of formula (I); or at least two aqueous compositions comprising at least one influenza virus antigen and a compound of formula (I) and combining the resulting compositions. Uses of and methods of treatment comprising the compositions are also disclosed for inducing an immune response against influenza virus.
Single dose of TS-161 100 mg or placebo in a fasted condition. Although planned, all subsequent dose levels after Cohort 1 will be determined based on the results from the preceding cohorts.
Accessing peripheral pulmonary nodules is problematic because they are often not visible endobronchially, not large enough to be visualized by x-ray fluoroscopy for transbronchial biopsy (TBBx), and/or do not lie within an accessible airway. In this study, investigators hope to evaluate new technologies to aid in PPN biopsy using navigation bronchoscopy (NB) combined with navigation transthoracic needle aspiration (N-TTNA) sampling of a PPN.

Patients meeting inclusion criteria who consent will undergo a convex Endobronchial Ultrasound (EBUS) bronchoscopy for evaluation and sampling of the mediastinum and hilum. Following this, NB will be performed with an ultrathin bronchoscope (4mm outer diameter with a 2 mm working channel) with R-EBUS and fluoroscopy. If the lesion is localized by NB and/or radial EBUS in conjunction with NB, TBBX will be taken. At the conclusion of TBBX sampling, a fluoroscopic evaluation to assess for the presence of pneumothorax will be performed and if one is present, appropriate clinical measures will be taken at the discretion of the treating team (tube thoracostomy, observation, etc.) and no further sampling techniques will be utilized. If the lesion was not able to be localized via NB and/or the physician feels insufficient sample was acquired for diagnosis and there is no evidence of pneumothorax, the patient will undergo N-TTNA at the same PPN during the same procedure time. It is envisioned that between 8-12 patients will require a N-TTNA to complete diagnosis.
NEW MATERIAL:Crown dihydrocodeinone of natural type shown by the formula I and crown codeinone of natural type. USE:A drug having a structure of natural type, properties of opiate and properties of ionophore at the same time. PREPARATION:Dihydrocodeinone of natural type shown by the formula II is treated with boron tribromide, and reacted with NaH and a compound shown by the formula THP(OCH2CH2)4OTs (THP is tetrahydropyranyl; Ts is tosyl), to give a compound shown by the formula III. This compound is treated with paratoluenesulfonic acid, processed into a compound shown by the formula IV by the use of NH4Cl and Zinc, and reacted with paratoluenesulfonic acid choride, and the alcohol group is tosylated. The carbonyl group is protected with thioketal, made into crown by the use of NaH, and deprotected to give a compound by the formula I . Similarly crown codeinone of natural type is obtained from (-)-codeinone.
Adipokines (or adipocytokines) can be defined as a group of more than 600 bioactive molecules made from adipose tissue that acts as paracrine and endocrine hormones. Adipokines are involved in maintaining varieties of processes such as, appetite and satiety, energy expenditure activity, endothelial function, blood pressure, hemostasis, adipogenesis, insulin sensitivity, energy metabolism in insulin-sensitive tissues, fat distribution and insulin secretion in pancreatic β-cells. Adipokines may contribute to reduce scar formation and improve cardiac function in coronary artery disease (CAD). Reperfusion therapy such as percutaneous coronary intervention (PCI) should be administered to all eligible patients with CAD symptom. However, our previous work showed that obese patients may benefit more from PCI. Thus, the aim of the present study was to investigate the efficacy and mechanism of adipokines cardiac protection for obese and non-obese patients with coronary artery disease (CAD).
Endoscopic training in flexible cystoscopy by directed self-regulated training, max. time cap 1h45min after a 15 minute oral theoretical lecture by a expert in the procedure. Total max. time: 2 hours.
Adults who sustain a spinal cord injury (SCI) now have the potential to lead active, productive lives with near normal life expectancy. Recent studies have demonstrated that many people with SCI develop health and functional problems at earlier ages than their non-disabled peers, with symptoms often occurring between the mid-30's and the mid-50's. These symptoms and impairments include: pain, musculoskeletal problems, declining energy, loss of strength and new functional limitations. These are examples of the challenges people may face as they reach mid-life with a SCI. A prevalent impairment in the long-term SCI population is upper extremity pain. Both the incidence and severity of pain increase with longer duration of SCI. The impact of shoulder pain on function and independence after SCI can be significant and detrimental. Development of shoulder pain in the SCI population has been associated with the increased weight-bearing demand placed on the upper extremities for mobility, muscle imbalances in the shoulder girdle, poor postural alignment from trunk paralysis and the need to function from a seated position. The efficacy of specific interventions has not been fully investigated. Treatment effectiveness must be determined using measures that include the pain impairment (severity), the disability or functional limitation associated with pain, and the participation or handicap limitations associated with pain. The goal is to develop a program that has standardized resistance, requires little equipment, is simple to conduct and minimizes the time commitment required of the patient. The effect of the combined intervention on shoulder pain and function will be assessed with a randomized clinical trial comparing the intervention to an attention control group receiving generalized information regarding shoulder joint anatomy and pain management. Secondary goals of this study are to identify the critical muscle groups for which strength changes are associated with shoulder pain reduction and to determine the impact of the intervention on physical activity, health related quality of life and overall subjective quality of life.
Intervention: Thiamine 500mg IV every 12 hours for 2 days. Oxygen consumption will be monitored with a non-invasive monitor continuously for 2 days and lactate, pyruvate dehydrogenase and other routine lab values will be checked at serial time points.
* Calcium Gluconate in Sodium Chloride Injection contains 20 mg of calcium gluconate per mL which contains 1.86 mg (i.e. 0.093 mEq) of elemental calcium. See Table 1 for amounts of elemental calcium in Calcium Gluconate in Sodium Chloride Injection. 



  * Do not dilute Calcium Gluconate in Sodium Chloride Injection prior to use. Any unused portion should be discarded. [see Dosage and Administration (2.5)].
  * Inspect Calcium Gluconate in Sodium Chloride Injection visually prior to administration. The solution should appear clear and colorless. Do not administer if there is particulate matter or discoloration. 
  * Administer Calcium Gluconate in Sodium Chloride Injection intravenously via a secure intravenous line to avoid calcinosis cutis and tissue necrosis [see Warnings and Precautions (5.3)]. 
  * Administer Calcium Gluconate in Sodium Chloride Injection by continuous infusion at the rate recommended in Table 2 [see Dosage and Administration (2.2)] and monitor patients, vitals, calcium and ECG during the infusion [see Warnings and Precautions (5.4)]. 
  * Check solution container composition, lot number, and expiry date. 
  * Do not admix with other drugs. 
  * Do not use solution containers in series connections. 
  * The intact port cap provides visual tamper evidence. Do not use if port cap is prematurely removed. Maintain strict aseptic technique during handling. 



INSTRUCTIONS FOR USE: 

  1. Always inspect the solution container before and after removal from the overwrap. 
  2. Place the solution container on a clean, flat surface. Remove the solution container from the overwrap. 
  3. Check the solution container for leaks by squeezing firmly. If leaks are found, discard. 
  4. Do not use if the solution is cloudy or a precipitate is present. 



To Prepare for Administration: 

  1. Immediately before inserting the infusion set, break off BLUE Infusion Port Cap with the arrow pointing away from the solution container. 
  2. Use a non-vented infusion set or close the air-inlet on a vented set. 
  3. Close the roller clamp of the infusion set 
  4. Hold the base of the BLUE infusion port, twist and push spike until fully inserted. 
  5. The BLUE infusion port contains a self-sealing septum that helps prevent leakage after removing the spike. The infusion port is not intended to be spiked more than once. 
  6. Suspend solution container from hanger hole. 
  7. For Single Use Only. Discard unused portion.
PURPOSE:A cosmetic, containing galloylarbutin prepared by linking gallic acid to arbutin or extracting Bergenia purpurascens, etc., and preferably further a water-soluble high polymer and having improved skin beautifying effect, whitening and beautifying effect, humectant effect, etc. CONSTITUTION:A cosmetic containing (A) 0.1-5wt% galloylarbutin and (B) 0.001-1wt% water-soluble high polymer. The ingredient (A) is obtained by linking gallic acid to arbutin (4-hydroxyphenyl-beta-D-glucopyranoside) by a chemical reaction or microbial technique, etc. or extracting from plant bodies of Bergenia purpurascens, etc., and is white - light yellow powder and readily soluble in alcohol, etc., with high safety. The ingredient (B) has >=2,000 molecular weight and polypeptides, water-soluble collagen, mucopolysaccharides, etc., may be cited. The above-mentioned cosmetic has effect on maintenance of tensity of the skin in a good state and lightening of the color of local liver-spots.
Glioblastoma multiforme (GBM) is a highly aggressive brain tumor characterized by invasive behavior and a compromised immune response, presenting treatment challenges. Surgical debulking of GBM fails to address its highly infiltrative nature, leaving neoplastic satellites in an environment characterized by impaired immune surveillance, ultimately paving the way for tumor recurrence. Tracking and eradicating residual GBM cells by boosting antitumor immunity is critical for preventing postoperative relapse, but effective immunotherapeutic strategies remain elusive. Here, we report a cavity-injectable bacterium-hydrogel superstructure that targets GBM satellites around the cavity, triggers GBM pyroptosis, and initiates innate and adaptive immune responses, which prevent postoperative GBM relapse in male mice. The immunostimulatory Salmonella delivery vehicles (SDVs) engineered from attenuated Salmonella typhimurium (VNP20009) seek and attack GBM cells. Salmonella lysis-inducing nanocapsules (SLINs), designed to trigger autolysis, are tethered to the SDVs, eliciting antitumor immune response through the intracellular release of bacterial components. Furthermore, SDVs and SLINs administration via intracavitary injection of the ATP-responsive hydrogel can recruit phagocytes and promote antigen presentation, initiating an adaptive immune response. Therefore, our work offers a local bacteriotherapy for stimulating anti-GBM immunity, with potential applicability for patients facing malignancies at a high risk of recurrence.
All subjects were given 600 mg of calcium and 400 IU of vitamin D supplements. The subjects were randomized to receive weekly alendronate 20 mg (n = 31) or placebo (n = 32).
The invention provides a bicyclol solid preparation. The bicyclol solid preparation comprises a micronized bicyclol drug, a solubiliser and other pharmacal common carriers. The micronized bicyclol drug having particle sizes d90 less than 30 microns, d50 less than 10 microns and d10 less than 2.5 microns. A use ratio of the solubiliser is in a range of 0 to 2%. Compared with the existing products in market, the bicyclol solid preparation has good solubility and high bioavailability. A preparation method of the bicyclol solid preparation has stable processes and strong controllability.
We conducted a double blind placebo-controlled randomized trial of antenatal betamethasone compared to dexamethasone among women at risk of preterm deliveries at Stony Brook University Hospital from August 1, 2002 through July 31, 2004. We excluded women with clinical chorioamnionitis, major fetal structural anomalies, fetal chromosomal abnormalities, prior antenatal steroid exposure, and use of betamethasone or dexamethasone for other medical indications, quadruplets and higher order multiple gestation and those who declined enrollment. Consenting women were randomly allocated to one of two groups by the Pharmacy using computer generated random numbers. The statistical analysis was performed in accordance of the intention-to-treat principle. Student t test, Chi square and Fisher exact test were used for analysis. A P value of \< .05 was considered statistically significant.
Pregabalin was introduced as an antiepileptic drug with analgesic anti-hyperalgesic and anxiolytic properties and was also used to treat neuropathic pain. In recent years it has been used as part of a multimodal management of acute postoperative pain after various types of surgery. We study the effect of pregabalin administered before cardiac surgery on acute and chronic postoperative pain. Post CABG syndrome is well known since 1980 and various analgesic methods have been used from time to time (opioids, regional analgesia, non-steroidal anti-inflammatory drugs). In our research patients will be divided into three groups. The control group will receive a placebo capsule before surgery. The second group will receive 75mg of pregabalin per os before surgery while the third will receive 150mg of pregabalin. After the surgery all patients will be connected to an intravenous PCA morphine pump for 48 hours. The postoperative pain will be assessed with the Visual Analogue Scale (0-10) every day. Total morphine consumption by the patients as well as any other pain medications administered supplementary will be registered and compared between the different groups. Remaining postoperative pain will be assessed after 3 months. The results will be statistically analyzed in order to determine whether there is significant difference in pain management between the groups.